Novel Therapeutic Options for the Management
of Inflammatory Bowel Disease

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 25, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Takeda Pharmaceuticals USA, Inc.

Inflammatory bowel disease (IBD) is a chronic inflammation of all or part of the digestive tract. IBD is primarily considered to be ulcerative colitis (UC) and Crohn’s disease (CD). There is no cure for IBD and treatment strategies include two major goals with one being trying to achieve clinical remission and the other being the prevention of disease flare ups. The top-down approach is considered to be the first way to treat patients by giving them an early introduction to biologics and immunodulators. The care of a patient with IBD can be either medical or surgical in nature or, commonly, a combination of both. The medical approach for patients with IBD is symptomatic (flaring) care and generally follows a step-wise approach to medication therapy, with progression of the medical regimen until a response is achieved. Long term control of inflammatory bowel diseases can be achieved with regular doses of medication, known as maintenance therapy, to keep flare-ups at bay and reduce the risk of more serious complications developing. For many patients with IBD, therapeutic options are limited to immunosuppressive therapy or biologic therapy with anti–tumor necrosis factor-alpha (TNF-α) agents. The continued advances in biologics are helping clinicians begin to shift their goals of IBD from clinical remission to complete remission which includes a combination of clinical remission, laboratory normalization and mucosal healing. An increasing number of clinical trial options have shown favorable short and long term outcomes.

Upon Completion of this activity, participants will be able to:

  • Discuss clinical data regarding current and novel therapies in inflammatory bowel disease

  • Assess new diagnostic methods, disease monitoring and the treat-to-target management paradigm in inflammatory bowel disease

  • Identify best practices for new and evolving endoscopic and surgical approaches, technologies, and techniques

  • Analyze novel treatment options for inflammatory bowel disease, including their risks and benefits, monitoring needs, and other complementary therapies

  • Explore treatment challenges in patients with inflammatory bowel disease and examine strategies for managing those issues for improved outcomes and quality of life

Faculty: Joel Pekow, MD
Assistant Professor of Medicine
Section of Gastroenterology
University of Chicago


Dr. Pekow receives resesarch/grant support from AbbVie and Takeda. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by an educational grant from
Takeda Pharmaceuticals USA, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue